Biosimilars: opinion of an expert panel in the Middle East

References

• Schellekens H. Follow-on biologics: challenges of the ‘next generation’. Nephrol Dial Transplant 2005;20 (Suppl 4):iv31-iv36
   PubMedGoogle Scholar
• EGA. Frequently asked questions about generic medicines. 2007; Available at www.egagenerics.com/FAQ-generics.htm
   Google Scholar
• EMEA. Questions and answers on generic medicines. EMEA Document EMEA/393905/2006 April 2007. Available at www.emea.europa.eu/pdfs/human/pcwp/39390506en.pdf [last accessed 24 July 2008]
   Google Scholar
• Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
   Google Scholar
• Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-72
   PubMed Web of Science ®Google Scholar
• Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21 (Suppl 5):v4-v8
   PubMed Web of Science ®Google Scholar
• Hepner F, Csaszar E, RoitingerE, et al. Mass spectrometrical analysis of recombinant human growth hormone Norditropin reveals amino acid exchange at M14_V14 rhGH. Proteomics 2006; 6:775-84
   PubMed Web of Science ®Google Scholar
• Hepner F, Cszasar E, RoitingerE, et al. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein. Proteome Sci 2005;3:1
   PubMedGoogle Scholar
• Hokke CH, Bergwerff AA, van DedemGW, et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett 1990;275:9-14
   PubMed Web of Science ®Google Scholar
• Hubbard SC, Walls L, RuleyHE, et al. Generation of Chinese hamster ovary cell glycosylation mutants by retroviral insertional mutagenesis. Integration into a discrete locus generates mutants expressing high levels of N-glycolylneuraminic acid. J Biol Chem 1994;269:3717-24
   Google Scholar
• Martin MJ, Muotri A, GageF, et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11:228-32
   PubMed Web of Science ®Google Scholar
• EMEA. Questions and answers on biosimilar medicines (similar biological medicinal products). EMEA Document EMEA/74562/2006 June 2007. Available at www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf [last accessed 24 July 2008]
   Google Scholar
• Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21 (Suppl 5):v13-v6
   PubMed Web of Science ®Google Scholar
• Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21 (Suppl 5):v9-v12
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Malucchi S, SalaA, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-53
   PubMed Web of Science ®Google Scholar
• Sharma B. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol Adv 2007;25:318-24
   Google Scholar
• Sharma B. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol Adv 2007;25: 325-31
   Google Scholar
• Casadevall N, Nataf J, VironB, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med 2002;346:469-75
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005; 18: 473-80
   PubMed Web of Science ®Google Scholar
• EMEA. Guideline on similar biological medicinal products. EMEA Document CHMP/437/04 October 2005. Available at www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA Document EMEA/CHMP/BMWP/42832/2005 February 2006. Available at www. emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA Document EMEA/CHMP/BMWP/49348/2005 February 2006. Available at www.emea.europa.eu/pdfs/human/biosimilar/4934805en.pdf [last accessed 24 July 2008]
   Google Scholar
• Woodcock J. Assessing the impact of a safe and equitable biosimilar policy in the United States. Presentation to the Subcommitte on Health, Committee on Energy and Commerce. May 2 2007. Available at: www.fda.gov/ola/2007/policy05022007.html [last accessed 5 March 2008]
   Google Scholar
• Hayakawa TSome aspects of development, evaluation and control of biologics in Japan. Presentation to the PMDA 1st International Symposium on Biologics, 15 February 2007, Tokyo, Japan 2007; Available at: www.pmda.go.jp/2007bio-sympo/agenda-e. html [last accessed 5 March 2008]
   Google Scholar
• Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;3:43-7
   Google Scholar
• Pavlovic M, Girardin E, KapetanovicL, et al. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res 2008;69:14-21
   PubMedGoogle Scholar
• FDA. Omnitrope (somatropin [rDNA origin]) questions and answers, 2006. Available at www.fda.gov/cder/drug/infopage/somatropin/qa.htm [last accessed 5 March 2008]
   Google Scholar
• Anon. British national formulary, vol. 54, September 2007: BMJ Publishing Group Ltd and RPS Publishing
   Google Scholar
• EMEA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA Document EMEA/CHMP/BMWP/14327/2006 December 2007. Available at www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. Guidance on similar medicinal products containing recombinant human soluble insulin. EMEA Document EMEA/CHMP/BMWP/32775/05 February 2006. Available at www.emea.europa.eu/pdfs/human/biosimilar/3277505en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. Guidance on similar medicinal products containing somatropin. EMEA Document EMEA/CHMP/BMWP/94528/05 February 2006. Available at www.emea.europa.eu/pdfs/human/biosimilar/9452805en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. EMEA Document EMEA/CHMP/BMWP/94526/05 February 2006. Available at www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. EMEA Document EMEA/CHMP/BMWP/31329/05 February 2006. Available at www.emea. europa.eu/pdfs/human/biosimilar/3132905en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Guideline on similar medicinal products containing recombinant interferon alpha. EMEA Document EMEA/CHMP/BMWP/102046/2006 October 2007. Available at www.emea.europa.eu/pdfs/human/biosimilar/10204606en.pdf [last accessed 24 July 2008]
   Google Scholar
• EMEA. Concept paper on similar biological medicinal products containing low molecular weight heparins: (non) clinical issues. EMEA Document EMEA/CHMP/BMWP/496286/2006 January 2007. Available at www.emea.europa.eu/pdfs/human/biosimilar/49628606en.pdf [last accessed 24 July 2008]
   Google Scholar